Basal insulin and cardiovascular and other outcomes in dysglycemia

HC Gerstein; J Bosch; GR Dagenais; R Díaz; H Jung; AP Maggioni; J Pogue; J Probstfield; A Ramachandran; MC Riddle; LE Rydén; S Yusuf; L Richardson; R Diaz; P Johnston; R Vige; K Birkeland; A Budaj; E Cardona; I Chazova; P Commerford; L Danilova; M Davies; R Fernando; G Fodor; R Gilbert; R Gomis; N Hâncu; M Hanefeld; P Hildebrandt; G Kacerovsky-Bielesz; M Keltai; JH Kim; H Krum; H Kültürsay; F Lanas; BS Lewis; E Lonn; P López-Jaramillo; J Marin-Neto; M Marre; R McKelvie; M McQueen; I Mendoza; C Morillo; C Pan; V Pirags; V Profozic; R Ratner; J Rosenstock; GA Spinas; S Sreenan; I Stoel; M Syvänne; JF Yale; A Avezum; MC Bahit; P Bogaty; L Bordeleau; C Chacόn; M Corson; WL Harper; D Halon; P Magloire; J Mann; V Pavlova; Z Punthakee; J Silva; B Tsang; N Yakubovich; A Abdallah; S Ahmad; J Chandra; R Chandra; T Cukierman-Yaffee; L Dyal; L Joldersma; L MacRae; S MacRae; S Malik; A Mead; F Pasha; J Pazmino-Canizares; K Pohl; A Sakalas; J Tyrwhitt; R Ahuad Guerrero; A Alebuena; N Alvarez; M Alzogaray; M Amuchastegui; M Andres; M Angos; H Baglivo; M Barbieri; F Bassi; F Bello; J Bono; M Bustamante Labarta; B Bustos

Journal article

Basal insulin and cardiovascular and other outcomes in dysglycemia

HC Gerstein, J Bosch, GR Dagenais, R Díaz, H Jung, AP Maggioni, J Pogue, J Probstfield, A Ramachandran, MC Riddle, LE Rydén, S Yusuf, L Richardson, R Diaz, P Johnston, R Vige, K Birkeland, A Budaj, E Cardona, I Chazova Show all

New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2012

DOI: 10.1056/NEJMoa1203858

Abstract

Background: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. Methods: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were..

View full abstract

University of Melbourne Researchers

Peter Colman Author

David O'Neal Author

Grants

Funding Acknowledgements

Supported by Sanofi. Dr. Dagenais reports receiving payment for serving on a data and safety monitoring board from Sanofi-Aventis and payment for serving on a steering committee from Eli Lilly; Dr. Gerstein, consulting and lecture fees from Sanofi-Aventis and other funds through his institution from Sanofi-Aventis, consulting and lecture fees from Bayer, consulting fees from Merck and other funds through his institution from Merck, consulting fees and other funds through his institution from Novo Nordisk, consulting fees from GlaxoSmithKline, Roche, Novartis, Janssen, Abbott, and AstraZeneca, grant support and other funds through his institution from Eli Lilly, and other funds through his institution from Boehringer Ingelheim; Dr. Maggioni, payment for serving on advisory boards from Oxford University, Sanofi-Aventis, Novartis, and Amgen; Dr. Probstfield, consulting fees from Amylin and Boehringer Ingelheim; Dr. Ramachandran, grant support through this institution from Merck Sharp & Dohme; Dr. Riddle, consulting and lecture fees from Sanofi-Aventis and grant support through his institution from Sanofi-Aventis; Dr. Ryden, consulting fees from Bristol-Myers Squibb and AstraZeneca, grant support from AFA Insurance and the Swedish Heart-Lung Foundation, and lecture fees from Roche and Sanofi-Aventis; and Dr. Yusuf, consulting and lecture fees and grant support from Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.